Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Avalon GloboCare Corp. is a clinical-stage biotechnology company focused on the development of cell-based therapies and immunotherapies for oncology and infectious diseases. The company operates within the biotechnology and life sciences industry, with an emphasis on leveraging cellular technologies to address unmet medical needs. Its activities are primarily research- and development-oriented, and the company has not reported significant commercial revenue from product sales, relying instead on equity financing and strategic transactions.
Founded in 2014, Avalon GloboCare initially pursued a broad immunotherapy strategy and has since evolved toward more specialized cellular therapy platforms. The company’s strategic positioning centers on integrating translational research, academic collaboration, and early-stage clinical development. Public disclosures indicate that Avalon GloboCare seeks to differentiate itself through cross-border scientific collaboration and access to novel cell therapy technologies, although several programs remain in preclinical or early clinical stages and their ultimate commercial viability is uncertain based on available public sources.
Business Operations
Avalon GloboCare’s operations are organized around research and development activities rather than traditional commercial segments. The company’s primary business lines include cell-based immunotherapies, CAR-T–related research, and exosome and immune modulation technologies, which are pursued through internal development and affiliated entities. Revenue generation has historically been limited, with operating expenses largely driven by laboratory research, personnel costs, and intellectual property development.
The company conducts operations primarily in the United States with collaborative and research ties in Asia. It controls laboratory assets, proprietary research platforms, and licensed intellectual property rather than large-scale manufacturing infrastructure. Avalon GloboCare has disclosed relationships with academic institutions and affiliated entities, including Global Technologies & Research, Inc., which supports aspects of its research and development activities. Data on the commercial scalability of these operations remains inconclusive based on available public sources.
Strategic Position & Investments
Avalon GloboCare’s strategic direction emphasizes advancing early-stage therapeutic candidates toward clinical validation while selectively investing in complementary biomedical technologies. Growth initiatives have included forming subsidiaries and entering into licensing or collaboration agreements designed to broaden its technology base without assuming the full cost of internal development. The company has also pursued restructuring and divestment of non-core assets to focus resources on priority therapeutic platforms.
Notable investments and subsidiaries disclosed in public filings include QiDiagnostics Limited and Global Technologies & Research, Inc., which support diagnostics and translational research capabilities. Avalon GloboCare has indicated interest in emerging sectors such as cell therapy optimization, immune system modulation, and precision medicine, though many initiatives remain exploratory. The long-term impact of these investments is uncertain and dependent on regulatory progress and financing conditions.
Geographic Footprint
Avalon GloboCare is headquartered in New Jersey, United States, which serves as its principal executive and administrative base. The company’s core research oversight and corporate governance functions are conducted from this location, with additional laboratory and collaborative activities occurring through affiliated entities.
Internationally, Avalon GloboCare has maintained a presence in Asia, particularly China, through research collaborations, subsidiaries, and historical investment activities. These cross-border operations are intended to facilitate access to scientific talent and research infrastructure. However, the scale of international operations is modest, and the company does not currently report large-scale manufacturing or commercial distribution activities across continents.
Leadership & Governance
Avalon GloboCare is led by a management team with backgrounds in biotechnology, finance, and translational medicine. The company’s governance structure includes an executive team and board of directors responsible for strategic oversight, capital allocation, and regulatory compliance. Leadership has articulated a vision centered on disciplined capital use, scientific collaboration, and advancing cell-based therapies toward clinical relevance.
Key executives include:
- David Jin – Chief Executive Officer
- Luisa Ingargiola – Chief Financial Officer
- Ruopeng An – President
- Ying Wang – Chief Scientific Officer
The leadership philosophy, as reflected in public disclosures, emphasizes incremental clinical progress and partnership-driven development. The effectiveness of this approach remains subject to execution risk and external factors common to early-stage biotechnology companies.